Trial Profile
PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) : A Cost-Effectiveness Analysis and Cost-Utility Analysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2009
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jul 2009 Planned end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record